Janssen
Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis
October 22, 2018Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis
Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …
Janssen’s Stelara shows promise across two dosages in ulcerative colitis
October 9, 2018Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis
Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …
MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar
October 8, 2018Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis
American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …
NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza
October 1, 2018Sales and Marketing HIV, Janssen, NHS, Symtuza, pharma
Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its …
Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis
September 13, 2018Research and Development Humira, Janssen, Tremfya, pharma, psoriasis
Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …
Europe approves Janssen’s Darzalex in frontline multiple myeloma
September 4, 2018Manufacturing and Production, Research and Development, Sales and Marketing EU, Europe, J&J, JJ, Janssen, darzalex, multiple myeloma, pharma
Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …
Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care
August 15, 2018Research and Development HIV, Janssen, ViiV Healthcare, pharma
Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, …
Janssen’s Symtuza scores approval with the FDA in HIV-1
July 18, 2018Sales and Marketing HIV, Janssen, Symtuza, pharma
Janssen has announced that Symtuza (D/C/F/TAF) has received approval from the FDA in the treatment of human immunodeficiency virus type …
J&J stops Invokana trial early after success in kidney disease and type 2 diabetes
July 17, 2018Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes
Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …
AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial
July 12, 2018Research and Development AbbVie, Cancer, FDA, Janssen, approval
AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its …
Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis
May 11, 2018Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis
NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …
Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma
May 8, 2018Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma
Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …
Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA
April 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, Kris Sterkens, pharma
Pharmafile.com sat down with Kris Sterkens, Company Group Chairman of Janssen’s EMEA operations to discuss nearly three decades at the …
The April 2018 issue of Pharmafocus is now live!
March 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Martin Shkreli, Right to try, atrial fibrillation, falsified medicines directive, oncology, opioids, pharma
As we finally pass into Spring after what still feels like a particularly stubborn Winter, we are pleased to announce …
Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis
February 19, 2018Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis
Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
